rivo-cel. key everyone, XXXX and I’ll we’ve priorities, our across our two us. goals afternoon, thanks as Good for progress an strategic pipeline with share and excited I’m update GoCAR-T XXXX. outline you provide Atabak. namely our well call our controllable as made today, today objectives therapies, On our to joining cell to for pipeline for Thanks, and
with time XXXX Before reflection and Bellicum I’ll my brief for our future as prospects. I begin on accomplishments do in a at context
the significant improved company a capabilities progress great and organization. with made development executive recruited deep our culture our in We new focused Over we’ve a clinical a in instilled team performance across built years, two in expertise, and particular last we’ve strengthening accountability. science, patient the we’ve
completion results. proofs While second XXXX, goals into efficiently Bellicum achievement in initial with interim included, company we programs, late product that trials, in and exciting had enrollment of rivo-cel is of for presentation a for for our always in progressing initiation IND these applications analyses these launch of expected preparation pediatric and data of trials of match XXXX, and Europe phase through is preclinical we rivo-cel from adult two MDS which science adolescent the great to our cell vector for dual work our and pediatric study of patients, THRIVE, manufacturing switch candidate GoCAR-T to execution, set technology the of In efforts study, and clinic record of and hard BPX-XXX corporate from progression the presentation our a with facility. rivo-cel X/X initiation and completion Phase viral AML for Houston and and patients, in of of objectives,
promotion Senior of our to Judith appointment top as we Board as CFO, talent, of In develop Foster Aaron Vice of addition President Head and to Research, and to and Mokari attainment, by Klimovsky to Directors. this Atabak goal recruit addition recent evidenced of continue of our
turn that I laid our more look external pipeline. In for coming Scientific years. in let’s formed to programs. progress our recently GoCAR-T our a now also We two the short, with scientists we’ve believe the Clinical even strategic context, priorities, Advisory clinicians valuable to starting perspective comprised Board and of With new and academic leading on back provide at foundation
and Our platform switch. activation iMC incorporates MyDXX CDXX or our inducible GoCAR-T
CAR-T may current iMC next-generation we several As a improve platform, believe upon generation in products ways.
molecules and persistence. proliferation costimulatory enhanced and T-cell MyDXX First, CDXX
research by may PD-X, microenvironment overriding modulate preclinical pathways, tumor such as iMC inhibitory suggests our common TGF-beta. the PGEX Second, and
we may complement activity chemokines pro-inflammatory that inducing enhanced cytokines efficacy CAR-T Third, by believe immune and iMC host time. to
the because which is infusion CAR-T molecule timing treatment. control switch profile clinicians may by Lastly, through frequency benefit small enable iMC our the can driven technology and better rimiducid, our of activation to and of the we manage risk cell
received know, line a pancreatic is which in and XX late data escalating the X expressing ESMO is conservatively. trial escalation target Phase In patients extreme lymphodepletion received dose reduced treated January doses disease of patients related iMC BPX-XXX a release single BPX-XXX cells meeting Patients patients metastatic profile, not line lymphodepletion, with treatment safety safety the only you December PSCA. demonstrated the the have study, Three of in our a single pancreatic study and consisting of high-grade GoCAR-T a advanced cells or second reported early only. activate dose with proved presented or of of ASCO encouraging, despite In and prostate cells of adverse sixth inadequate syndrome that BPX-XXX challenge to a activate total The At design. rimiducid promising conditioning in GI results events. cell a our treating BPX-XXX designed in Part a cyclophosphamide administration other once cancer data cancer. rimiducid ongoing received As the low X/X no were following Initial with interim BPX-XXX, with iMC of candidate regimen Immuno-Oncology PSCA. treatment. to to evaluation, we X+X first of stem dose product antigen from the other nine cytokine
efficacy two prolonged experienced six evaluable of in than of single in a shrinkage human. concept XX%. whom dose preliminary the and addition, of In of first stable achieving of led tumor data greater providing proof patients evidence patients, disease, with to expansion Furthermore, clinical and cell activity rimiducid several control enhanced cell persistence provided disease iMC four of
this standard Cy/Flu or experience human and our expressing strengthening iMC, conditioning still trial expanded cancer We’ve learning intent and with with have quite first gastric fludarabine bit. we seen. are we’ve of cyclophosphamide early the prostate a As eligibility to PSCA, efficacy patients to amended the signal is the include
results over patient to to in dosing report reactivate to rimiducid plan Once cohort, cohort trial complete repeat initial the we expect from we the scheduled midyear. evaluation this BPX-XXX We to of safety the iMC time. order Cy/Flu of allow for amend
was reminder activated a As iMC a the basis. to on designed regular be switch
over expand efficacy T-cell Our suggests experience rimiducid cells preclinical time GoCAR-T exhaustion, creating dosing can reactivate the and clinical without that potential. regular maximizing
results of cohort by of about of BPX-XXX a totality end for this GoCAR-T platform. to-date and patient the on Based this as data year. initial as candidate We our proof concept from expect a the optimistic we’re product
to controllable to XXXX. excited for GoCAR-T We’re switch candidates dual into advance planned submissions clinic, the IND with
platform both CaspaCIDe switch. the switch activation switch safety incorporates iMC dual and the Our
that it We’re a express of antigen and which the tumors potential and target is treatment-emergent have clinical manage further these because suited more may this technology modest toxicity. antitumor is academic by excited effort through benefits CaspaCIDe. off enable solid and target iMC We activity. HERX enhance on believe any dual of improve as is thoroughly approaches uniquely validated a protocols about efficacy. We platform switch CAR-T aggressive may been of for that are driving toxicity efficacy target limited CAR-T Previous demonstrated greater BPX-XXX activation, that CaspaCIDe, while earlier HERX. with tumor, have designed be clinicians studies selected cell given enabling to therapy benefits switch cancer efficacy for by efficacy treatment Bellicum’s upon iMC BPX-XXX combination product candidate to dual and to safety first
in XXXX, to file BPX-XXX, application we expect hematologic an a file and BPX-XXX switch candidates in initiate an XXXX. in We Later antigen IND to application expect malignancies. an for dual product clinical a expressed targeting IND trial for
to later rationale this submission. discuss will We IND closer the as get we year target
six a at our on turning XXXX. trial to analysis, priority EFS rivo-cel. unrelated patients is patients in or of having as in and a at positive of of other Hematology We study in our pediatric results Now donor Meeting profile. of Rivo-cel presented interim offered EFS December as transplantation. takeaways; interim well or The important final ASH event matched survival first, MUD attractive confidence ahead trending treated months late The the analyses presentation support undergoing American the patients Society commercially three XXX our the strategic free
a EFS for As the endpoint versus agreed-upon noninferiority reminder, on MUD is primary transplant European review. our regulatory
relapse Second, the durability almost with evidence further high rivo-cel, follow-up and efficacy the of free rates survival, overall a of of years. provided X data median with of of
efficacy were a the XX% demonstrated CaspaCIDe, advanced responded majority responses. results when developed of steroid which GvHD, the or that patients of complete as retreated rimiducid, with refractory of Lastly,
to intend results topline and second late in rimiducid authorization this submit for marketing study and from rivo-cel applications in expect European quarter XXXX. the We
recently cyclophosphamide, registration of trial, of we transplant a a an the THRIVE, acute study the intermediate initiated by will or risk and X/X either and matched in T-replete which regimen, the without clinical rivo-cell, or the to and to randomized Phase and U.S. and adolescent high adult expand is both trial, patients Looking The adult to patients. enrolling years XX older, global with potentially ahead, designed patients to HLA standard-of-care MDS. In haplo Baltimore the post-transplantation the Phase donor. in the U.S. X randomized receive followed the Europe portion regimen be is current adults rivo-cel AML
product. to globally, the Based that launching are and we the commercial therapeutics about number preparation supported to-date I’d drawing oncology we’ve and for factors. rivo-cel, My turn rivo-cel. for growing Lastly novel and on years commercial I’m excitement on excited upon confidence by the see of a this prospects and like done opportunity of experience my to hematology
First, population is significant. the patient addressable
is annually. per in addressable initial growing European opportunity patients market patients year X,XXX and is approximately pediatric X% Our
adolescent and would addressable per AML in to MDS second the year Europe almost patients, Our XX,XXX in patients U.S. and lunch adult this and add opportunity.
early and market riov-cel’s that the KOLs opportunity on substantial capture believe encouraging share. rivo-cel market feedback proposition clinical and based we from to research, has compelling Second, value physician
segment we have MUD believe who haplo penetrate the have otherwise transplantation we patients a standard-of-care to to also in received become of might the Specifically, opportunity and transplant. the
which by our therapies. will research pricing investment. Third, limited economic early our support reimbursement and market health analysis, with approved commercial we’re will encouraged Fourth, consistent cell require payers favorable payer launch indicate currently and initial
the market the centers opportunity. estimate transplant XX highly represent is As concentrated. Europe We the in of market top pediatric approximately XX% pediatric European
European experience successfully medical talented commercial of recruited excited with and recently we’re leadership launching about group record products. a team, a our track Lastly,
hand anticipated of rivo-cel on XXXX. Atabak that, them toward Board, we’re progress financials. making launch to to review With With our I’d great our over like the call in to
